(1) In addition to those dangerous drugs scheduled in 50-32-222, 50-32-224, 50-32-226, 50-32-229, and 50-32-232, MCA, the board adds the following to dangerous drug schedules after considering federal regulations and/or the criteria enumerated in Title 50, chapter 32, part 2, MCA:

(a) Schedule I:

(i) none at this time;

(b) Schedule II:

(i) none at this time;

(c) Schedule III:

(i) methasterone;

(ii) perampanel; and

(iii) prostanozol;

(d) Schedule IV:

(i) tramadol;

(ii) alfaxalone;

(iii) suvorexant; and

(iv) lorcaserin;

(e) Schedule V:

(i) ezogabine.

(2) The board deletes the following dangerous drugs from the schedules in 50-32-222, 50-32-224, 50-32-226, 50-32-229, and 50-32-232, MCA, after considering federal regulations and/or the criteria enumerated in Title 50, chapter 32, part 2, MCA:

(a) Schedule I:

(i) none at this time;

(b) Schedule II:

(i) naloxegol;

(c) Schedule III:

(i) 50-32-226(4)(c) and (d), MCA (hydrocodone combination products);

(d) Schedule IV:

(i) none at this time;

(e) Schedule V:

(i) none at this time.

(3) After considering federal regulations and/or the criteria enumerated in Title 50, chapter 32, part 2, MCA, the board reschedules the following dangerous drugs from those scheduled in 50-32-222, 50-32-224, 50-32-226, 50-32-229, and 50-32-232, MCA:

(a) Schedule I:

(i) none at this time;

(b) Schedule II:

(i) none at this time;

(c) Schedule III:

(i) none at this time;

(d) Schedule IV:

(i) modafinil;

(e) Schedule V:

(i) none at this time.